Published in Melanoma Res on October 01, 2014
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer (2015) 0.98
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017) 0.78
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging (2017) 0.77
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. Exp Hematol Oncol (2017) 0.75
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biol Med (2016) 0.75
Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options. Case Rep Oncol (2016) 0.75
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75
Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Per Med (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics (2015) 2.93
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol (2003) 2.68
BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer (2012) 2.55
Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use? J Nucl Med (2011) 2.52
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res (2012) 2.25
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2003) 2.14
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.12
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol (2004) 1.88
Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol (2005) 1.85
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol (2006) 1.73
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys (2003) 1.73
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med (2010) 1.67
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.67
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J (2004) 1.64
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 1.62
Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys (2008) 1.60
UBF levels determine the number of active ribosomal RNA genes in mammals. J Cell Biol (2008) 1.57
Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer (2011) 1.57
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma (2003) 1.52
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal (2011) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood (2006) 1.47
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck (2005) 1.45
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem (2004) 1.45
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med (2006) 1.43
Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET. J Nucl Med (2012) 1.43
Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med (2010) 1.42
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res (2013) 1.38
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res (2007) 1.38
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol (2012) 1.32
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol (2011) 1.31
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res (2006) 1.27
Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer (2013) 1.26
Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25